vs
爱德华生命科学（EW）与宜瑞安（INGR）财务数据对比。点击上方公司名可切换其他公司
宜瑞安的季度营收约是爱德华生命科学的1.1倍（$1.8B vs $1.6B），爱德华生命科学净利率更高（23.1% vs 9.5%，领先13.6%），爱德华生命科学同比增速更快（16.7% vs -2.4%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs -3.4%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
宜瑞安（Ingredion Inc.）是总部位于美国伊利诺伊州的食品饮料配料供应商，主打产品包括淀粉、非转基因甜味剂、甜菊糖、豌豆蛋白等，以玉米、木薯、马铃薯、谷物、果蔬等为原料，产品供应食品、饮料、酿造、制药等多个行业，在全球44个站点拥有约1.2万名员工，客户覆盖超120个国家。
EW vs INGR — 直观对比
营收规模更大
INGR
是对方的1.1倍
$1.6B
营收增速更快
EW
高出19.1%
-2.4%
净利率更高
EW
高出13.6%
9.5%
两年增速更快
EW
近两年复合增速
-3.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $1.8B |
| 净利润 | $380.7M | $167.0M |
| 毛利率 | 78.0% | 24.5% |
| 营业利润率 | 1.8% | 12.5% |
| 净利率 | 23.1% | 9.5% |
| 营收同比 | 16.7% | -2.4% |
| 净利润同比 | 6.8% | 72.2% |
| 每股收益（稀释后） | $0.66 | $2.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWINGR
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.6B | $1.8B | ||
| Q2 25 | $1.5B | $1.8B | ||
| Q1 25 | $1.4B | $1.8B | ||
| Q4 24 | $1.4B | $1.8B | ||
| Q3 24 | $1.4B | $1.9B | ||
| Q2 24 | $1.4B | $1.9B |
净利润EWINGR
| Q1 26 | $380.7M | — | ||
| Q4 25 | $91.2M | $167.0M | ||
| Q3 25 | $291.1M | $171.0M | ||
| Q2 25 | $333.2M | $196.0M | ||
| Q1 25 | $358.0M | $197.0M | ||
| Q4 24 | $385.6M | $97.0M | ||
| Q3 24 | $3.1B | $188.0M | ||
| Q2 24 | $366.3M | $148.0M |
毛利率EWINGR
| Q1 26 | 78.0% | — | ||
| Q4 25 | 78.1% | 24.5% | ||
| Q3 25 | 77.8% | 25.1% | ||
| Q2 25 | 77.5% | 26.0% | ||
| Q1 25 | 78.7% | 25.7% | ||
| Q4 24 | 78.9% | 24.9% | ||
| Q3 24 | 80.6% | 25.6% | ||
| Q2 24 | 79.9% | 23.7% |
营业利润率EWINGR
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | 12.5% | ||
| Q3 25 | 19.8% | 13.7% | ||
| Q2 25 | 26.8% | 14.8% | ||
| Q1 25 | 27.9% | 15.2% | ||
| Q4 24 | 22.6% | 9.0% | ||
| Q3 24 | 25.9% | 14.3% | ||
| Q2 24 | 26.8% | 12.8% |
净利率EWINGR
| Q1 26 | 23.1% | — | ||
| Q4 25 | 5.8% | 9.5% | ||
| Q3 25 | 18.7% | 9.4% | ||
| Q2 25 | 21.7% | 10.7% | ||
| Q1 25 | 25.3% | 10.9% | ||
| Q4 24 | 27.8% | 5.4% | ||
| Q3 24 | 226.7% | 10.1% | ||
| Q2 24 | 26.7% | 7.9% |
每股收益（稀释后）EWINGR
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.16 | $2.58 | ||
| Q3 25 | $0.50 | $2.61 | ||
| Q2 25 | $0.56 | $2.99 | ||
| Q1 25 | $0.61 | $3.00 | ||
| Q4 24 | $0.65 | $1.43 | ||
| Q3 24 | $5.13 | $2.83 | ||
| Q2 24 | $0.61 | $2.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.0B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $4.3B |
| 总资产 | — | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EWINGR
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $1.0B | ||
| Q3 25 | $3.8B | $915.0M | ||
| Q2 25 | $4.1B | $861.0M | ||
| Q1 25 | $3.9B | $837.0M | ||
| Q4 24 | $4.0B | $997.0M | ||
| Q3 24 | $4.4B | $877.0M | ||
| Q2 24 | $2.0B | $505.0M |
股东权益EWINGR
| Q1 26 | — | — | ||
| Q4 25 | $10.3B | $4.3B | ||
| Q3 25 | $10.2B | $4.2B | ||
| Q2 25 | $10.5B | $4.2B | ||
| Q1 25 | $10.1B | $4.0B | ||
| Q4 24 | $10.0B | $3.8B | ||
| Q3 24 | $9.5B | $4.0B | ||
| Q2 24 | $7.4B | $3.7B |
总资产EWINGR
| Q1 26 | — | — | ||
| Q4 25 | $13.7B | $7.9B | ||
| Q3 25 | $13.3B | $7.8B | ||
| Q2 25 | $13.5B | $7.8B | ||
| Q1 25 | $13.0B | $7.5B | ||
| Q4 24 | $13.1B | $7.4B | ||
| Q3 24 | $13.0B | $7.5B | ||
| Q2 24 | $10.1B | $7.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $405.0M |
| 自由现金流经营现金流 - 资本支出 | — | $270.0M |
| 自由现金流率自由现金流/营收 | — | 15.4% |
| 资本支出强度资本支出/营收 | — | 7.7% |
| 现金转化率经营现金流/净利润 | — | 2.43× |
| 过去12个月自由现金流最近4个季度 | — | $511.0M |
8季度趋势，按日历期对齐
经营现金流EWINGR
| Q1 26 | — | — | ||
| Q4 25 | $450.9M | $405.0M | ||
| Q3 25 | $573.7M | $277.0M | ||
| Q2 25 | $290.2M | $185.0M | ||
| Q1 25 | $280.4M | $77.0M | ||
| Q4 24 | $-127.5M | $436.0M | ||
| Q3 24 | $351.8M | $479.0M | ||
| Q2 24 | $371.5M | $312.0M |
自由现金流EWINGR
| Q1 26 | — | — | ||
| Q4 25 | $353.5M | $270.0M | ||
| Q3 25 | $516.2M | $172.0M | ||
| Q2 25 | $240.9M | $84.0M | ||
| Q1 25 | $224.4M | $-15.0M | ||
| Q4 24 | $-177.3M | $311.0M | ||
| Q3 24 | $299.9M | $429.0M | ||
| Q2 24 | $286.1M | $257.0M |
自由现金流率EWINGR
| Q1 26 | — | — | ||
| Q4 25 | 22.5% | 15.4% | ||
| Q3 25 | 33.2% | 9.5% | ||
| Q2 25 | 15.7% | 4.6% | ||
| Q1 25 | 15.9% | -0.8% | ||
| Q4 24 | -12.8% | 17.3% | ||
| Q3 24 | 22.1% | 22.9% | ||
| Q2 24 | 20.9% | 13.7% |
资本支出强度EWINGR
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 7.7% | ||
| Q3 25 | 3.7% | 5.8% | ||
| Q2 25 | 3.2% | 5.5% | ||
| Q1 25 | 4.0% | 5.1% | ||
| Q4 24 | 3.6% | 6.9% | ||
| Q3 24 | 3.8% | 2.7% | ||
| Q2 24 | 6.2% | 2.9% |
现金转化率EWINGR
| Q1 26 | — | — | ||
| Q4 25 | 4.94× | 2.43× | ||
| Q3 25 | 1.97× | 1.62× | ||
| Q2 25 | 0.87× | 0.94× | ||
| Q1 25 | 0.78× | 0.39× | ||
| Q4 24 | -0.33× | 4.49× | ||
| Q3 24 | 0.11× | 2.55× | ||
| Q2 24 | 1.01× | 2.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EW
暂无分部数据
INGR
| Food And Industrial Ingredients LATAM Segment | $599.0M | 34% |
| Texture And Healthful Solutions Segment | $598.0M | 34% |
| Food And Industrial Ingredients U.S.Canada Segment | $486.0M | 28% |
| Other | $74.0M | 4% |
